Systemic treatment of acute liver failure with adipose derived stem cells

Journal of Investigative Surgery

Volumn 28, Issue 2, 2015, Pages 120-126

  Pascual Miguelañez, Isabel ^a   Salinas Gomez, Javier ^b   Fernandez Luengas, David ^a   Villar Zarra, Karen ^c   Clemente, Luz Vega ^d   Garcia Arranz, Mariano ^d   Olmo, Damian Garcia ^b,d  

^a HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

Adult stem cells; Fulminant liver failure; Liver failure; Liver transplant; Mesenchymal stem cells

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE;

ACUTE LIVER FAILURE; ADIPOSE DERIVED STEM CELL; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; HISTOPATHOLOGY; LIVER PARENCHYMA; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTEMIC THERAPY; ADIPOSE TISSUE; ANIMAL; BIOLOGICAL THERAPY; BLOOD; CELL DIFFERENTIATION; CYTOLOGY; DISEASE MODEL; DRUG-INDUCED LIVER INJURY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER; LIVER CELL; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADIPOSE TISSUE; ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CARBON TETRACHLORIDE; CELL DIFFERENTIATION; CELL- AND TISSUE-BASED THERAPY; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; HEPATOCYTES; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84928593022     PISSN: 08941939     EISSN: 15210553     Source Type: Journal    
DOI: 10.3109/08941939.2014.987407     Document Type: Article

References (29)

1. Burra P, Arcidiacono D, Bizzaro D, Chioato T, et al. Systemic administration of a novel human umbilical cordmesenchymal stem cells population accelerates the resolution of acute liver injury. BMC Gastroenterol. 2012;12:88.
2. Banas A, Teratani T, Yamamoto Y, et al. Rapid hepatic fate specification of adipose-derived stem cells and their therapeutic potential for liver failure. J Gastroenterol Hepatol. 2009;24:70-77.
3. Viswanathan P, Gupta S. New directions for cell-based therapies in acute liver failure. J Hepatol. 2012;57:913-915.
4. Loukopoulos I, Sfiniadakis I, Pillai A, et al. Mycophenolate mofetil and sirolimus in hepatocyte transplantation in an experimental model of toxic acute liver failure. J Invest Surg. 2014;27:205-213.
5. Herrera MB, Fonsato V, Bruno S, et al. Human liver stem cells improve liver injury in a model of fulminant liver failure. Hepatology 2013;57:311-319.
6. Pietrosi G, Vizzini GB, Gruttadauria S, et al. Clinical applications of hepatocyte transplantation. World J Gastroenterol. 2009;15:2074-2077.
7. Palmes D, Qayumi AK, Spiegel HU. Liver bridging techniques in the treatment of acute liver failure. J Invest Surg. 2000;13:299-311.
8. Piryaei A, Valojerdi MR, Shahsavani M, et al. Differentiation of bone marrow-derived mesenchymal stem cells into hepatocyte-like cells on nanofibers and their transplantation into a carbon tetrachloride-induced liver fibrosis model. Stem Cell Rev. 2011;7:103-118.
9. Gruttadauria S, Grosso G, Pagano D, et al.Marrow-derived mesenchymal stem cells restore biochemical markers of acute liver injury in experimental model. Transplant Proc. 2013;45:480-486.
10. Liu ZC, Chang TM. Intrasplenic transplantation of bioencapsulated mesenchymal stem cells improves the recovery rates of 90% partial hepatectomized rats. Stem Cells Int. 2012. doi: 10.1155/2012/697094.
11. Alemán CL, Más RM, Rodeiro I, et al. Reference database of the main physiological parameters in Sprague-Dawley rats from 6 to 32 months. Lab Anim. 1998;32:457-466.
12. Wahi PN, Tandon HD, Bharadwaj TP. Acute carbon tetrachloride hepatic inury; composite histological, histochemical and biochemical study. I. Histological and histochemical studies. Acta Pathol Microbiol Scand. 1955;37:305-314.
13. Yun JW, Kim CW, Bae IH, et al. Determination of the key innate genes related to individual variation in carbon tetrachloride-induced hepatotoxicity using a pre-biopsy procedure. Toxicol Appl Pharmacol. 2009;239:55-63.
14. Garcia-Olmo D, Garcia-Arranz M, Herreros MD, et al. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48:1416-1423.
15. Pascual I, deMiguel GF, Gómez-Pinedo UA, et al. Adiposederived mesenchymal stem cells in biosutures do not improve healing of experimental colonic anastomoses. Br J Surg. 2008;95:1180-1184.
16. Pascual I, Fernández de Miguel G, Garcá Arranz M, et al. Biosutures improve healing of experimental weak colonic anastomoses. Int J Colorectal Dis. 2010;25:1447-1451.
17. Pareja E, Cortés M, Martńez A, et al. Hepatic cell transplantation: a new therapy in liver diseases. Cir Esp. 2010;88:3-11.
18. Pareja E, Martńez A, Cortés M, et al. Hepatic cell transplantation. Technical and methodological aspects. Cir Esp. 2010;87:139-147.
19. Banas A, Teratani T, Yamamoto Y, et al. IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury. Stem Cells. 2008;26:2705-2712.
20. Kim SJ, Park KC, Lee JU, et al.Therapeutic potential of adipose tissue-derived stem cells for liver failure according to the transplantation routes. J Korean Surg Soc. 2011;81(3):176-186.
21. Mark AL, Sun Z, Warren DS, et al. Stem cell mobilization is life saving in an animal model of acute liver failure. Ann Surg. 2010;252(4):591-596.
22. Duncan AW, Dorrell C, Grompe M. Stem cells and liver regeneration. Gastroenterology. 2009;137(2):466-481.
23. Terblanche J, Hickman R. Animalmodels of fulminant hepatic failure. Dig Dis Sci. 1991;36:770-774.
24. Weil BR, Manukyan MC, Herrmann JL, et al. The immunomodulatory properties of mesenchymal stem cells: implications for surgical disease. J Surg Res. 2011;167(1): 78-86.
25. Yi T, Song SU. Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res. 2012;35(2):213-221.
26. Georgiev-Hristov T, Garcá-Arranz M, Garcá-Gómez I, et al. Sutures enriched with adipose-derived stem cells decrease the local acute inflammation after tracheal anastomosis in a murine model. Eur J Cardiothorac Surg. 2012;42(3):40-47.
27. Trebol Lopez J, Georgiev Hristov T, et al. Stem cell therapy for digestive tract diseases: current state and future perspectives. Stem Cells Dev. 2011;20:1113-1129.
28. Gonzalez Rey E, Anderson P, Gonzalez MA, et al. Human adult ítem cells derived from adipose tissue Project against experimental colitis and sepsis. Gut. 2009;58:929-939.
29. Noort WA, Kruisselbrink AB, In't Anker PS, et al. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol. 2002;30(8):870-878.